Prospective Evaluation of Adult Pulmonary Langerhans Cell Histiocytosis (LCHA1)

Assistance Publique - Hôpitaux de Paris

Status: Completed

Conditions: Adult Pulmonary Langerhans Cell Histiocytosis

Treatments: Behavioral: Tabacco discontinuation

Study type: Observational

Funder types: Other

Identifiers

NCT01225601

AOM 04141

Details and patient eligibility

About

Study objectives:

• To estimate the incidence of pulmonary deterioration in adult pulmonary Langerhans cell histiocytosis
• To assess the impact of tobacco discontinuation
• Study Design Multicentric prospective cohort study
• Main endpoint: Pulmonary deterioration
• Sample size : 40 patients

Full description

Study objectives To estimate the incidence of pulmonary deterioration in adult pulmonary Langerhans cell histiocytosis To assess the impact of tobacco discontinuation Study Design Multicentric prospective cohort study Main endpoint: Pulmonary deterioration Sample size : 40 patients

Enrollment: 62 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pulmonary Langerhans cell histiocytosis diagnosed within the past 48 months

Exclusion criteria

• Age < 18
• Deep pulmonary dysfunction (CPT< 60%, FEV1< 30%, DLCO< 30%, partial pressure of oxygen in arterial blood (PaO2)< 60mmHg)
• No informed consent or consent withdrawal

Trial design

62 participants in 1 patient group

Histocytosis

Description:

Adult with isolated pulmonary Langerhans cell histiocytosis (pulmonary LCH)

Treatment:

Behavioral: Tabacco discontinuation